Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cataract & MIGS cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 78 | 24,138 | 24% |
| 2020 | 73 | 21,957 | 27% |
| 2021 | 80 | 25,172 | 30% |
| 2022 | 78 | 23,760 | 34% |
| 2023 | 70 | 16,927 | 38% |
| 2024 | 68 | 18,172 | 40% |
| 2025 from claims | – | 19,450 17,850–20,578 | 41% |
| 2026 forecast | – | 19,975 17,575–23,051 | 40% |
| 2027 forecast | – | 20,133 17,212–23,993 | 40% |
| 2028 forecast | – | 20,291 16,931–24,846 | 41% |
| 2029 forecast | – | 20,450 16,702–25,646 | 41% |
| 2030 forecast | – | 20,608 16,510–26,409 | 42% |
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 47% of the cases CMS names in Iowa; 29 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 39% hospital outpatient, 57% surgery center, 4% office. The share outside the hospital has moved +20 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Minnesota | 153 | 81,628+7.9%/yr | +7.9%/yr | 176.3 | 69% | 138,000 in 2030+9.1%/yr |
| Ohio | 292 | 74,196−1.5%/yr | −1.5%/yr | 65.8 | 76% | 79,700 in 2030+1.2%/yr |
| Illinois | 317 | 67,303−0.8%/yr | −0.8%/yr | 48.0 | 70% | 75,800 in 2030+2%/yr |
| Indiana | 139 | 45,606−2.5%/yr | −2.5%/yr | 63.6 | 83% | 44,900 in 2030−0.3%/yr |
| Michigan | 304 | 41,610−7.1%/yr | −7.1%/yr | 48.2 | 76% | 38,700 in 2030−1.2%/yr |
| Wisconsin | 145 | 38,264+1.4%/yr | +1.4%/yr | 66.5 | 58% | 52,200 in 2030+5.3%/yr |
| Missouri | 163 | 35,677−3.1%/yr | −3.1%/yr | 56.5 | 81% | 35,000 in 2030−0.3%/yr |
| Kansas | 67 | 23,142−1.6%/yr | −1.6%/yr | 56.6 | 78% | 24,400 in 2030+0.9%/yr |
| Nebraska | 48 | 17,332+0.1%/yr | +0.1%/yr | 65.8 | 75% | 20,900 in 2030+3.2%/yr |
| South Dakota | 28 | 11,938−0.1%/yr | −0.1%/yr | 90.9 | 84% | 13,900 in 2030+2.5%/yr |
| North Dakota | 23 | 8,264+1.9%/yr | +1.9%/yr | 82.0 | 78% | 9,110 in 2030+1.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Vitreoretinal surgery | 14 | 772+0.4%/yr | +0.4%/yr | 1.80.7× | 67% | 880 in 2030+2.2%/yr |
Cataract & MIGS in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Minnesota
Rayner Intraocular Lenses leads with 63% of company spending on these surgeons in 2025, +51 pts on 2024.
In 2025, 15 companies reported engagement with Iowa’s surgeons worth $276K in consulting, speaking, meals and travel tied to these products, about $4,065 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.